Oncolytics Biotech Company Insiders

Oncolytics Biotech Management Team Effectiveness

The company has return on total asset (ROA) of (0.7133) % which means that it has lost $0.7133 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3822) %, meaning that it created substantial loss on money invested by shareholders. Oncolytics Biotech's management efficiency ratios could be used to measure how well Oncolytics Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.75 in 2024. Return On Capital Employed is likely to drop to -1.03 in 2024. At this time, Oncolytics Biotech's Other Current Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 32 M in 2024, whereas Total Assets are likely to drop slightly above 30.5 M in 2024. Common Stock Shares Outstanding is likely to rise to about 71 M in 2024, despite the fact that Net Loss is likely to grow to (21.2 M).

Oncolytics Biotech Workforce Comparison

Oncolytics Biotech Benchmark Summation

Oncolytics Biotech Notable Stakeholders

The success or failure of an entity such as Oncolytics Biotech often depends on how effective the management is. Oncolytics Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Oncolytics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Oncolytics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in Oncolytics Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Oncolytics Biotech. Check Oncolytics Biotech's Beneish M Score to see the likelihood of Oncolytics Biotech's management manipulating its earnings.

When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.